Drug

D0805 | bisacodyl

Molecular Formula C22H19NO4
Molecular Weight 361.4
Structure
State solid
Clearance primarily in the feces, systemically absorbed drug is excreted in the urine.
Half life 16 hours
Absorption 0.15

A

A06AG02 Bisacodyl


[A06AG] Enemas


[A06A] DRUGS FOR CONSTIPATION


[A06] DRUGS FOR CONSTIPATION


[A] Alimentary tract and metabolism


A06AB52 Bisacodyl, combinations


[A06AB] Contact laxatives


[A06A] DRUGS FOR CONSTIPATION


[A06] DRUGS FOR CONSTIPATION


[A] Alimentary tract and metabolism


A06AB02 Bisacodyl


[A06AB] Contact laxatives


[A06A] DRUGS FOR CONSTIPATION


[A06] DRUGS FOR CONSTIPATION


[A] Alimentary tract and metabolism


Toxicity Dose Time Species Model Method Action Positive criterion Reference
MEMBRANE POTENTIAL 14.82±3.63 human qHTS-HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 7.74 human HepG2 MMP assay decrease IC50 163
MEMBRANE POTENTIAL 18.39±13.00 rat hepatocytes MMP assay decrease IC50 163
MEMBRANE POTENTIAL 312.4 µM 30 mins mouse liver mitochondria Rh123 fluorescence (excitation 485 nm, emission 535 nm) are recorded using a fluorescence multi-well plate reader (mCICCP (20 µM) treatments was considered as the 100% baseline for ΔΨm loss) decrease EC20 36
RESPIRATION 50.9 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. decrease EC20 36
RESPIRATION 52.5 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. decrease EC20 36
SWELLING > 400 µM 30 mins mouse liver mitochondria swelling assay: Absorbance at 545 nm using a fluorescence multi-well plate reader (CaCl2 (50 µM) was considered as the 100% baseline for the swelling ) increase EC20 36

Target Dose Time Species Model Method Action Positive criterion Reference
NADH:ubiquinone reductase 50.9 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Rotenone (2µM) was used as 100% baseline for complex I inhibition. inhibit EC20 36
Succinate dehydrogenase 52.5 µM 60 mins mouse liver mitochondria Oxygen consumption was monitored with 50nM MitoXpress ( an oxygen-sensitive phosphorescent dye) using a spectrofluorimeter (Tecan Infinite 200; λExcitation 380nm; λEmission 650nm). Oligomycin A (1µM) was used as 100% baseline for complex II inhibition. inhibit EC20 36
Cytochrome c > 400 µM 30 mins mouse liver mitochondria Cytochrome c release was evaluated using ELISA kit ( 20 µg/ml Alamethicin was used as 100% baseline) release EC20 36

Pictogram Signal Statements Precautionary Statement Codes
Warning

Aggregated GHS information provided by 56 companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.


H302 (10.71%): Harmful if swallowed [Warning Acute toxicity, oral]


H315 (94.64%): Causes skin irritation [Warning Skin corrosion/irritation]


H319 (96.43%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]


H335 (83.93%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure


Respiratory tract irritation]


Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.


P261, P264, P270, P271, P280, P301+P312, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.)

Organism Test type Route Dose (normalized dose) Effect Source
mouse LD50 intraperitoneal 983mg/kg (983mg/kg) Blood. Vol. 76, Pg. 2389, 1990.
rat LD50 oral 2gm/kg (2000mg/kg) cardiac: other changes Archives of Toxicology, Supplement. Vol. 18, Pg. 202, 1996.
rat LD50 intraperitoneal 600mg/kg (600mg/kg) Drugs of the Future. Vol. 13, Pg. 413, 1988.
mammal (species unspecified) LD50 unreported > 1gm/kg (1000mg/kg) Archives of Toxicology, Supplement. Vol. 18, Pg. 202, 1996.
guinea pig LDLo oral 1gm/kg (1000mg/kg) BioMetals. Vol. 10, Pg. 247, 1997.


  • (4,4'-Diacetoxydiphenyl)(2-pyridyl)methane (Pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate (pyridin-2-ylmethanediyl)dibenzene-4,1-diyl diacetate
    (pyridin-2-ylmethylene)di-4,1-phenylene diacetate 10X0709Y6I 2-(4,4'-Diacetoxydiphenylmethyl)pyridine
    4,4'-(2-Pyridylmethylene)bisphenol diacetate 4,4'-(2-Pyridylmethylene)diphenol diacetate 4,4'-(2-Pyridylmethylene)diphenol diacetate (ester)
    4,4'-(2-pyridylmethylene)bisphenol diacetate 4,4'-(pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate 4,4'-Diacetoxydiphenylpyrid-2-ylmethane
    4,4'-Diacetoxydiphenylpyridyl-2-methane 4,4-(2-Pyridylmethylene)diphenol diacetate 4-[(4-acetyloxyphenyl)-2-pyridylmethyl]phenyl acetate
    4-[[4-(Acetyloxy)phenyl](2-pyridinyl)methyl]phenyl acetate # 4-[[4-(acetyloxy)phenyl](2-pyridyl)methyl]phenyl acetate 603-50-9
    A14914 A832704 AB00051928
    AB00051928-17 AB00051928_18 AB00051928_19
    AC-24284 AK116442 AKOS001599884
    API0001726 AS-15820 AX8117347
    B1898 B5066 BCP18567
    BDBM61400 BPBio1_000416 BRD-K39987650-001-05-0
    BRD-K39987650-001-15-9 BRN 0323727 BSPBio_000378
    BSPBio_001916 Bicol Bis(p-acetoxyphenyl)-2-pyridylmethane
    Bisacodilo Bisacodilo [INN-Spanish] Bisacodyl (JP17/USP/INN)
    Bisacodyl [USAN:INN:BAN:JAN] Bisacodyl [USP:INN:BAN:JAN] Bisacodyl for peak identification, European Pharmacopoeia (EP) Reference Standard
    Bisacodyl for system suitability, European Pharmacopoeia (EP) Reference Standard Bisacodyl, European Pharmacopoeia (EP) Reference Standard Bisacodyl, United States Pharmacopeia (USP) Reference Standard
    Bisacodyl, active ingredient of Viraplex Bisacodyl, analytical standard, for drug analysis Bisacodyl,(S)
    Bisacodylum Bisacodylum [INN-Latin] Brocalax
    C22H19NO4 CAS-603-50-9 CCG-35661
    CCG-36442 CCRIS 8864 CHEBI:3125
    CHEMBL942 CS-2667 CTK8F8189
    Correctol Tablets, Caplets D00245 DB09020
    DSSTox_CID_2681 DSSTox_GSID_22681 DSSTox_RID_76689
    DTXSID1022681 Deficol Di-(4-acetoxyphenyl)-2-pyridylmethane
    Di-(p-acetoxyphenyl)-2-pyridylmethane DivK1c_000347 Dulcolan
    Dulcolax Dulcolax Dulcolax (TN)
    Durolax EBD8044 EINECS 210-044-4
    Endokolat Eulaxan FT-0603486
    Feen-a-Mint Tablets Fenilaxan Godalax
    HMS1569C20 HMS1920G21 HMS2090K15
    HMS2091O03 HMS2096C20 HMS2235I11
    HMS3373L17 HMS3652E04 HMS3713C20
    HMS501B09 HSDB 3016 HY-B0557
    HalfLytely HalfLytely (Salt/Mix) Hillcolax
    Horton IDI1_000347 Ivilax
    KBio1_000347 KBio2_000506 KBio2_003074
    KBio2_005642 KBio3_001416 KBioGR_000692
    KBioSS_000506 KHOITXIGCFIULA-UHFFFAOYSA-N KS-00000FS0
    LA96a LACO LS-2218
    Laxadin Laxanin N Laxans
    Laxine Laxorex MCULE-8607347748
    MFCD00038039 MLS000069729 MLS002701749
    NCGC00016522-01 NCGC00016522-02 NCGC00016522-03
    NCGC00016522-04 NCGC00016522-05 NCGC00016522-06
    NCGC00016522-07 NCGC00016522-08 NCGC00016522-09
    NCGC00016522-10 NCGC00016522-11 NCGC00016522-12
    NCGC00023260-03 NCGC00023260-04 NCGC00023260-05
    NCGC00023260-06 NCGC00257892-01 NCI60_004954
    NCIChal_000004 NCIMech_000456 NINDS_000347
    NSC-614826 NSC-755914 NSC614826
    NSC755914 Neolax Nigalax
    Opera_ID_884 Pharmakon1600-01500147 Phenol, 4,4'-(2-pyridinylmethylene)bis-, 1,1'-diacetate
    Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate Phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester) Phenol, 4,4'-(2-pyridylmethylene)di-, diacetate
    Phenol, 4,4'-(2-pyridylmethylene)di-, diacetate (ester) Phenol,4'-(2-pyridinylmethylene)bis-, diacetate (ester) Prestwick0_000419
    Prestwick1_000419 Prestwick2_000419 Prestwick3_000419
    Prestwick_780 Pyrilax Q-200726
    Q-200727 Q417874 REGID_for_CID_2391
    SBB057015 SBI-0051297.P003 SC-18411
    SCHEMBL21044 SMR000058226 SPBio_000258
    SPBio_002317 SPECTRUM1500147 SR-01000000233
    SR-01000000233-2 SR-01000000233-3 ST024745
    ST24026365 STK293202 SW196918-3
    Sanvacual Sk-bisacodyl Spectrum2_000149
    Spectrum3_000318 Spectrum4_000256 Spectrum5_000898
    Spectrum_000086 Stadalax Telemin
    Theralax Tox21_110472 Tox21_110472_1
    Tox21_200338 UNII-10X0709Y6I Ulcolax
    ZINC3830321 Zetrax [4-[(4-Acetyloxyphenyl)-pyridin-2-ylmethyl]phenyl] acetate;
    [4-[(4-acetyloxyphenyl)-pyridin-2-yl-methyl]phenyl] ethanoate [4-[(4-acetyloxyphenyl)-pyridin-2-ylmethyl]phenyl] acetate acetic acid [4-[(4-acetyloxyphenyl)-(2-pyridinyl)methyl]phenyl] ester
    bisacodyl cid_2391 s4047

    DrugBank Name bisacodyl
    DrugBank DB09020
    CAS Number 30652-11-0, 603-50-9
    PubChem Compound 2391
    KEGG Drug D00245
    ChEBI 3125